+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Splenomegaly Therapeutics Market 2019-2023 - Product Image

Global Splenomegaly Therapeutics Market 2019-2023

  • ID: 4760880
  • Report
  • March 2019
  • Region: Global
  • 116 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • MORE
The availability of clinical practice guidelines improves the quality of life of patients, as well as the consistency of care. There are several guidelines and care pathways for the management of splenomegaly, which have been developed by hospitals and professional societies. These are published and practiced with the aim of standardizing disease management in patients with splenomegaly.

For instance, the Hospital for Sick Children has developed a clinical practice guideline for clinicians to provide adequate disease management in children with splenomegaly. In developing countries such as India, the Association of Physicians of India published guidelines for a clinical approach for appropriate diagnosis and management of splenomegaly. The analysts have predicted that the splenomegaly therapeutics market will register a CAGR of almost 3% by 2023.

Market Overview

Rising awareness of splenomegaly

The incidence of splenomegaly has been seen along with many primary indications, including infections, autoimmune disorders, and hematological malignancies, which are increasing globally. Hence, the governments of various countries and several non-governmental organizations are striving to increase patient awareness about splenomegaly.

Challenges associated with diagnosis of splenomegaly

Splenomegaly is a nonspecific finding, which is challenging to assess diagnostically, as it is generally a manifestation of an underlying primary disorder. The highly advanced procedures such as point-of-care ultrasonography for the diagnosis for splenomegaly have high sensitivity compared with conventional imaging techniques. However, the poor patient access because of the high cost limits their utilization in diagnosing splenomegaly.

For the detailed list of factors that will drive and challenge the growth of the splenomegaly therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fairly fragmented and with the presence of several vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: PIPELINE ANALYSIS

PART 05: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 07: MARKET SEGMENTATION BY PRODUCT
  • Market segmentation by product
  • Comparison by product
  • Drug therapy - Market size and forecast 2018-2023
  • Vaccination - Market size and forecast 2018-2023
  • Market opportunity by product
PART 08: CUSTOMER LANDSCAPE

PART 09: MARKET SEGMENTATION BY TYPE
  • Congestive splenomegaly
  • Infiltrative splenomegaly
  • Neoplastic splenomegaly
  • Immune splenomegaly
PART 10: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 13: MARKET TRENDS

PART 14: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 15: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
PART 16: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global rare diseases therapeutics market
Exhibit 02: Segments of global rare diseases therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline molecules for reduction in spleen size
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: Product - Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Drug therapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: JAKAVI/JAKAFI sales in $ millions
Exhibit 22: Drug therapy - Year-over-year growth 2019-2023 (%)
Exhibit 23: Vaccination - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Vaccination - Year-over-year growth 2019-2023 (%)
Exhibit 25: Market opportunity by product
Exhibit 26: Customer landscape
Exhibit 27: Market share by geography 2018-2023 (%)
Exhibit 28: Geographic comparison
Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 36: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: GlaxoSmithKline plc - Vendor overview
Exhibit 46: GlaxoSmithKline plc - Business segments
Exhibit 47: GlaxoSmithKline plc - Organizational developments
Exhibit 48: GlaxoSmithKline plc - Geographic focus
Exhibit 49: GlaxoSmithKline plc - Segment focus
Exhibit 50: GlaxoSmithKline plc - Key offerings
Exhibit 51: Incyte Corporation - Vendor overview
Exhibit 52: Incyte Corporation - Business segments
Exhibit 53: Incyte Corporation - Organizational developments
Exhibit 54: Incyte Corporation - Key offerings
Exhibit 55: Merck & Co., Inc. - Vendor overview
Exhibit 56: Merck & Co., Inc. - Business segments
Exhibit 57: Merck & Co., Inc. - Organizational developments
Exhibit 58: Merck & Co., Inc. - Geographic focus
Exhibit 59: Merck & Co., Inc. - Segment focus
Exhibit 60: Merck & Co., Inc. - Key offerings
Exhibit 61: Novartis AG - Vendor overview
Exhibit 62: Novartis AG - Business segments
Exhibit 63: Novartis AG - Organizational developments
Exhibit 64: Novartis AG - Geographic focus
Exhibit 65: Novartis AG - Segment focus
Exhibit 66: Novartis AG - Key offerings
Exhibit 67: Sanofi - Vendor overview
Exhibit 68: Sanofi - Business segments
Exhibit 69: Sanofi - Organizational developments
Exhibit 70: Sanofi - Geographic focus
Exhibit 71: Sanofi - Segment focus
Exhibit 72: Sanofi - Key offerings
Exhibit 73: Validation techniques employed for market sizing
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
  • MORE
Global Splenomegaly Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global splenomegaly therapeutics market: GlaxoSmithKline plc, Incyte Corporation, Merck & Co., Inc., Novartis AG, Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the expanding research on molecular pathogenesis of splenomegaly.”

According to the report, one of the major drivers for this market is the availability of clinical guidelines of management of splenomegaly.

Further, the report states that one of the major factors hindering the growth of this market is the lack of curative therapies.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Merck & Co., Inc.
  • Novartis AG
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll